Helios Biotechnology JSC (HOSE:HSL)
Vietnam · Delayed Price · Currency is VND 7,200.00
-100.00 (-1.37%)
At close: Nov 4, 2026
Helios Biotechnology JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '17 Dec 31, 2017 | Jan '17 Jan 1, 2017 |
| 1,985 | 45,939 | 139,246 | 389,734 | 221,883 | 167,112 | |
Revenue Growth | -96.55% | -67.01% | -64.27% | 75.65% | 32.78% | - |
Cost of Revenue | 2,726 | 44,621 | 128,067 | 371,175 | 197,160 | 148,573 |
Gross Profit | -740.38 | 1,318 | 11,179 | 18,559 | 24,723 | 18,539 |
Selling, General & Admin | 5,732 | 4,474 | 4,518 | 4,756 | 1,320 | 791.34 |
Operating Expenses | 5,732 | 4,474 | 4,518 | 4,756 | 1,320 | 791.34 |
Operating Income | -6,473 | -3,157 | 6,660 | 13,803 | 23,403 | 17,747 |
Interest Expense | -29,371 | -10,769 | -1,159 | -1,673 | - | -221.79 |
Interest & Investment Income | - | 13,838 | 2,440 | 865.55 | 277.19 | 3.63 |
Earnings From Equity Investments | -5,537 | -5,630 | -23.81 | 880.93 | - | - |
Other Non Operating Income (Expenses) | 42,049 | 14,566 | 91 | -113.74 | -1.12 | -3.1 |
EBT Excluding Unusual Items | 669.24 | 8,849 | 8,009 | 13,763 | 23,679 | 17,526 |
Gain (Loss) on Sale of Investments | -910.69 | -910.69 | -522.03 | -803.31 | - | - |
Gain (Loss) on Sale of Assets | -2,244 | -2,244 | - | - | - | - |
Other Unusual Items | -48.89 | -48.89 | -101.37 | - | - | - |
Pretax Income | -2,535 | 5,645 | 7,385 | 12,960 | 23,679 | 17,526 |
Income Tax Expense | 432.16 | 5,504 | 409.09 | 897.26 | - | - |
Earnings From Continuing Operations | -2,967 | 141.71 | 6,976 | 12,062 | 23,679 | 17,526 |
Minority Interest in Earnings | -88.55 | -126.09 | -218 | -307.64 | - | - |
Net Income | -3,055 | 15.61 | 6,758 | 11,755 | 23,679 | 17,526 |
Net Income to Common | -3,055 | 15.61 | 6,758 | 11,755 | 23,679 | 17,526 |
Net Income Growth | - | -99.77% | -42.51% | -50.36% | 35.11% | - |
Shares Outstanding (Basic) | 43 | 39 | 39 | 40 | 21 | 9 |
Shares Outstanding (Diluted) | 43 | 39 | 39 | 40 | 21 | 9 |
Shares Change | 23.80% | - | -3.18% | 93.51% | 120.49% | - |
EPS (Basic) | -71.52 | 0.40 | 175.23 | 295.10 | 1150.38 | 1877.37 |
EPS (Diluted) | -71.52 | 0.40 | 175.00 | 295.10 | 1150.38 | 1877.37 |
EPS Growth | - | -99.77% | -40.70% | -74.35% | -38.72% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '17 Dec 31, 2017 | Jan '17 Jan 1, 2017 |
Free Cash Flow | 7,873 | -49,074 | 41,562 | -1,200 | 6,102 | -38,652 |
Free Cash Flow Per Share | 184.27 | -1272.43 | 1077.64 | -30.13 | 296.45 | -4140.33 |
Gross Margin | -37.29% | 2.87% | 8.03% | 4.76% | 11.14% | 11.09% |
Operating Margin | -326.02% | -6.87% | 4.78% | 3.54% | 10.55% | 10.62% |
Profit Margin | -153.90% | 0.03% | 4.85% | 3.02% | 10.67% | 10.49% |
Free Cash Flow Margin | 396.54% | -106.83% | 29.85% | -0.31% | 2.75% | -23.13% |
EBITDA | -5,698 | -1,123 | 12,031 | 19,159 | 26,180 | 19,385 |
EBITDA Margin | -287.02% | -2.44% | 8.64% | 4.92% | 11.80% | 11.60% |
D&A For EBITDA | 774.32 | 2,034 | 5,370 | 5,356 | 2,776 | 1,638 |
EBIT | -6,473 | -3,157 | 6,660 | 13,803 | 23,403 | 17,747 |
EBIT Margin | - | -6.87% | 4.78% | 3.54% | 10.55% | 10.62% |
Effective Tax Rate | - | 97.49% | 5.54% | 6.92% | - | - |
Revenue as Reported | 1,985 | 45,939 | 139,246 | 389,734 | 221,883 | 167,112 |